Dashboard
Manage Tickers

BIIBBIOGEN INC.

Nasdaq biogen.com


$ 231.81 $ 3.10 (1.36 %)    

Friday, 28-Jun-2024 15:59:52 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 479.98 $ -3.41 (-0.71 %)
DIA $ 391.11 $ -0.45 (-0.11 %)
SPY $ 544.70 $ -1.67 (-0.31 %)
TLT $ 91.77 $ -1.75 (-1.87 %)
GLD $ 215.03 $ 0.04 (0.02 %)
$ 231.82
$ 229.76
$ 221.80 x 100
$ 235.60 x 100
$ 228.55 - $ 235.34
$ 189.44 - $ 287.60
2,227,454
na
33.82B
$ 0.68
$ 28.99
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 04-24-2024 03-31-2024 10-Q
2 02-14-2024 12-31-2023 10-K
3 11-08-2023 09-30-2023 10-Q
4 07-25-2023 06-30-2023 10-Q
5 04-25-2023 03-31-2023 10-Q
6 02-15-2023 12-31-2022 10-K
7 10-25-2022 09-30-2022 10-Q
8 07-20-2022 06-30-2022 10-Q
9 05-03-2022 03-31-2022 10-Q
10 02-03-2022 12-31-2021 10-K
11 10-20-2021 09-30-2021 10-Q
12 07-22-2021 06-30-2021 10-Q
13 04-22-2021 03-31-2021 10-Q
14 02-03-2021 12-31-2020 10-K
15 10-21-2020 09-30-2020 10-Q
16 07-22-2020 06-30-2020 10-Q
17 04-23-2020 03-31-2020 10-Q
18 02-06-2020 12-31-2019 10-K
19 10-22-2019 09-30-2019 10-Q
20 07-24-2019 06-30-2019 10-Q
21 04-24-2019 03-31-2019 10-Q
22 02-06-2019 12-31-2018 10-K
23 10-23-2018 09-30-2018 10-Q
24 07-24-2018 06-30-2018 10-Q
25 04-24-2018 03-31-2018 10-Q
26 02-01-2018 12-31-2017 10-K
27 10-24-2017 09-30-2017 10-Q
28 07-25-2017 06-30-2017 10-Q
29 04-25-2017 03-31-2017 10-Q
30 02-02-2017 12-31-2016 10-K
31 10-26-2016 09-30-2016 10-Q
32 07-21-2016 06-30-2016 10-Q
33 04-21-2016 03-31-2016 10-Q
34 02-03-2016 12-31-2015 10-K
35 10-21-2015 09-30-2015 10-Q
36 07-24-2015 06-30-2015 10-Q
37 04-24-2015 03-31-2015 10-Q
38 02-04-2015 12-31-2014 10-K
39 10-22-2014 09-30-2014 10-Q
40 07-23-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

needham-reiterates-buy-on-biogen-maintains-294-price-target
Needham Reiterates Buy on Biogen, Maintain...
06/28/2024 09:33:03

Needham analyst Ami Fadia reiterates Biogen (NASDAQ:BIIB) with a Buy and maintains $294 price target.

reported-earlier-eisai-and-biogen-launch-alzheimers-drug-leqembi-in-china
Reported Earlier, Eisai and Biogen Launch ...
06/28/2024 07:12:52

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: ...

Core News & Articles
'Biogen Is Pursuing More Dealmaking This Y...
06/27/2024 15:39:59

https://endpts.com/biogen-is-pursuing-more-dealmaking-this-year-with-plans-to-spend-up-to-8B/  

rbc-capital-reiterates-outperform-on-biogen-maintains-317-price-target
RBC Capital Reiterates Outperform on Bioge...
06/27/2024 13:57:28

RBC Capital analyst Brian Abrahams reiterates Biogen (NASDAQ:BIIB) with a Outperform and maintains $317 price target.

forecasting-the-future-19-analyst-projections-for-biogen
Forecasting The Future: 19 Analyst Project...
06/26/2024 16:01:28

rbc-capital-reiterates-outperform-on-biogen-maintains-317-price-target
RBC Capital Reiterates Outperform on Bioge...
06/26/2024 15:07:54

RBC Capital analyst Brian Abrahams reiterates Biogen (NASDAQ:BIIB) with a Outperform and maintains $317 price target.

biogen-has-up-to-10b-for-its-next-ma-bets---bloomberg-news
'Biogen Has Up To $10B For Its Next M&A Be...
06/25/2024 16:20:57

https://www.bloomberg.com/news/newsletters/2024-06-25/biogen-has-up-to-10-billion-for-its-next-m-a-bets

Core News & Articles
Biogen Exec Says The Alzheimer's Drug Mark...
06/12/2024 15:30:20

- Goldman Sachs Conference

Core News & Articles
Biogen Exec Says LEQEMBI Is Going To Do V...
06/12/2024 15:28:03

- Goldman Sachs Conference

eli-lillys-donanemab-gains-favorable-fda-advisory-verdict-boosting-stock-potential-says-bofa-analyst
Eli Lilly's Donanemab Gains Favorable FDA ...
06/11/2024 18:19:10

Eli Lilly's donanemab for Alzheimer's disease garners positive FDA committee verdict, prompting analyst's bullish o...

why-is-eli-lilly-stock-trading-higher-premarket-tuesday
Why Is Eli Lilly Stock Trading Higher Prem...
06/11/2024 11:51:12

Shares of Eli Lilly surged as an FDA advisory committee endorsed donanemab, an Alzheimer's treatment shown to significantly...

Core News & Articles
Eisai And Biogen Announced FDA Accepts Fil...
06/10/2024 00:09:59

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: ...

biib---analyzing-biogens-short-interest
(BIIB) - Analyzing Biogen's Short Interest
06/07/2024 15:15:18

rbc-capital-reiterates-outperform-on-biogen-maintains-317-price-target
RBC Capital Reiterates Outperform on Bioge...
06/05/2024 14:36:32

RBC Capital analyst Brian Abrahams reiterates Biogen (NASDAQ:BIIB) with a Outperform and maintains $317 price target.

biogen-shares-surge-following-collaboration-with-delta-flight-products-what-you-need-to-know
Biogen Shares Surge Following Collaboratio...
06/03/2024 18:43:27

Biogen Inc. (NASDAQ: BIIB) shares saw a notable uptick Monday afternoon, trading higher after the company revealed a new partne...

10-health-care-stocks-with-whale-alerts-in-todays-session
10 Health Care Stocks With Whale Alerts In...
06/03/2024 17:35:22

Core News & Articles
Biogen and Delta Flight Products to Collab...
06/03/2024 11:37:11

 Biogen Inc. (NASDAQ:BIIB) and Delta Flight Products (DFP), a wholly-owned subsidiary of Delta Air Lines established to create ...

europe-approves-biogens-tofersen-for-adult-patients-with-rare-type-of-neurodegenerative-disorder
Europe Approves Biogen's Tofersen For Adul...
05/31/2024 14:25:09

The European Commission has granted exceptional marketing authorization for Biogen's Qalsody (tofersen), the first EU-appro...

biogen-announces-european-commission-grants-marketing-authorization-for-qalsody-to-treat-sod1-als-in-adults-maintains-orphan-designation
Biogen Announces European Commission Grant...
05/30/2024 20:52:50

SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS estimated to affect less than 1,000 people in Eu...

rbc-capital-reiterates-outperform-on-biogen-maintains-317-price-target
RBC Capital Reiterates Outperform on Bioge...
05/29/2024 13:59:47

RBC Capital analyst Brian Abrahams reiterates Biogen (NASDAQ:BIIB) with a Outperform and maintains $317 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

06/28/2024 Malibu Boats, Inc. (MBUU)
07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)